Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADJUPANET: Adjuvant Chemotherapy in Resected Pancreatic Neuroendocrine Tumors
NCT07591493Phase 3Not yet recruiting
- Sponsor
- Gustave Roussy
- Start
- Sep 2026
- Primary completion
- Jun 2035
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of capecitabine and temozolomide in Pancreatic neuroendocrine tumor (PanNET) (2 arms), sponsored by Gustave Roussy. Primary endpoint: Disease-Free Survival up to 5 years. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
capecitabinetemozolomide
03
Conditions
Pancreatic neuroendocrine tumor (PanNET)
Beyond the preview
Go deeper on NCT07591493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07591493.